Brad Baltz
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Role not yet determined Is this you? Add your title
Also affiliated: Merck & Co., Inc., Rahway, NJ, USA (United States) (2019); Cleveland Clinic (2007); University of Tennessee Health Science Center (2014); University Hospitals of Cleveland (2007); Juravinski Cancer Centre (2007); Catholic Health Initiatives (2022); University of Chicago Medical Center (2007); Piedmont Cancer Institute (2007); Lady of Mercy Medical Center (2007); CHI St. Vincent (2021); Nuvance Health (2022)
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Brad Baltz's research has focused on clinical outcomes and treatment efficacy across various patient populations. He has investigated the safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies, contributing to a randomized, double-blind, phase 3 trial. Baltz has also examined the use of sorafenib in the management of advanced renal cell carcinoma, including a subset analysis of patients with brain metastases. His work includes studies on sickle cell disease, with publications detailing baseline characteristics and clinical outcomes from long-term, prospective registry trials. Additionally, Baltz has reported on a case of primary mediastinal large B-cell lymphoma in a patient undergoing treatment for multiple sclerosis and investigated pembrolizumab-induced myocarditis and polyradiculoneuropathy.
Metrics
- h-index: 5
- Publications: 9
- Citations: 90
Selected Publications
-
Pembrolizumab-Induced Myocarditis and Delayed Acute Inflammatory Demyelinating Polyradiculoneuropathy (2022)
-
Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis (2021)
Collaboration Network
Top Collaborators
- Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis
- Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis
- Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis
- Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis
- Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis
- Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis
- Pembrolizumab-Induced Myocarditis and Delayed Acute Inflammatory Demyelinating Polyradiculoneuropathy
- Pembrolizumab-Induced Myocarditis and Delayed Acute Inflammatory Demyelinating Polyradiculoneuropathy
Similar Researchers
Based on overlapping research topics